Alexander Laurenson presents T cell-focused tool at the 2025 Vaccinology Conference using data from 18 countries and 748 HLA alleles to address immune diversity in Africa.

The international organization’s first-ever set of guidelines for this serious condition are looking to reduce mortality and morbidity.

New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate

The company's Nuvaxovid vaccine is the only recombinant protein-based, non-mRNA COVID-19 immunization available in the US.

SOF/VEL cured 98.9% of 7,027 hepatitis C cases globally, and peptide-decorated liposomes improved antifungal delivery against Candida species, and more

A Centers for Disease Control and Prevention (CDC) publication reports on REPEXH01, a strain of Shiga toxin–producing Escherichia coli (STEC) O157:H7, which has been responsible for at least 9 outbreaks in the US since 2017.

In our latest From Pathogen to Infectious Disease Diagnosis podcast, bioMérieux Chief Medical Officer Chuck Cooper, MD, discusses the burden of resistance, and insights on the company’s novel Vitek Compact Pro ID/AST system, which looks to identify infectious disease in a timely manner, and aid clinicians in diagnosing patients and streamlining antimicrobial treatment and avoiding severe complications such as sepsis.

More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Zandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.

Clinical-stage company, Biovie, will study its therapy, bezisterim, for treatment of neurological symptoms associated with the condition. The company expects to have study results in the first half of 2026.

Posaconazole-loaded liposomes decorated with penetratin show up to 1300 times increased efficacy against biofilm formation and reduce fungal burden by 60% in murine models.

Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases discusses the results of the organization's new survey and the surprising findings that many people forget to wash their hands after key times or believe it is not needed.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

A small percentage of people who contract the tick-borne illness have lingering symptoms and health issues after the acute infection has been treated, but there are no FDA-approved therapies to deal with prolonged symptoms. A new report looks to address this issue.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Pertussis, also known as whooping cough, saw more cases last year than in the last decade, and it is on track for another record year for cases. Sharon Nachman, MD, provides clinical insights for presentation, treatment, and vaccination.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

A large retrospective cohort study demonstrates greater resistance across different pathogens in this patient population compared with those who do not have cancer.

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit

Paul Offit, MD, offers a glimpse of when the outbreak might end as well as where we are with herd immunity, the MMR vaccine’s efficacy, and insights on breakthrough cases.

75% effectiveness of RSV vaccines in adults aged 60 and older, along with key safety considerations and broadened recommendations for high-risk groups.

Regulatory action follows reports of serious adverse events during use in elderly individuals; vaccine remains authorized for younger age groups in the US and Europe with over 40,000 doses administered globally.

Phase 3 data link gut microbiome shifts to better mental health outcomes in patients treated with fecal microbiota, live-jslm.

The company detailed its preliminary 24-week post–end-of-treatment data for its tobevibart and elebsiran combination, which is being studied for chronic hepatitis B.